Full Data For Intercept's Liver Disease Drug Show Rivals Where To Differentiate

Full Phase III data for Intercept Pharmaceuticals Inc.'s recently approved rare liver disease drug, Ocaliva, have highlighted potential treatment gaps for upcoming pipeline drugs, including candidates from Gilead Sciences Inc., Novartis AG, Shire Pharmaceuticals plc and GlaxoSmithKline plc.